Result card

  • CUR16 / ORG12: Who decides which people are eligible for intravenous immunoglobulin (IVIG) therapy and on what basis?
English

Who decides which people are eligible for intravenous immunoglobulin (IVIG) therapy and on what basis?

Authors: Antonio Migliore, Tapani Keranen, Sinikka Sihvo, Pseudo117 Pseudo117, Pseudo451 Pseudo451, Pseudo136 Pseudo136, Pseudo262 Pseudo262

Internal reviewers: Kristian Lampe, Pseudo291 Pseudo291, Pseudo340 Pseudo340

Acknowledgments: ,

As IVIG have not been approved for Alzheimer’s disease including Mild Cognitive Impairment, IVIG therapy does not have a formal prescription pathway for such indications. Considering the contextual differences among the countries, a generalisation of the off-label prescription strategies of the IVIG therapy is not possible and remains out of the scope of the present results card.

The current setting for the administration of IVIG therapy (for any condition) is use within hospitals {Appendix CUR-3}.

Important
Completely
Migliore A et al. Result Card CUR16 / ORG12 In: Migliore A et al. Health Problem and Current Use of the Technology In: Jefferson T, Cerbo M, Vicari N [eds.]. Use of Intravenous immunoglobulins for Alzeheimer’s disease including Mild Cognitive Impairment [Core HTA], Agenas - Agenzia nazionale per i servizi sanitari regionali ; 2015. [cited 24 October 2020]. Available from: http://corehta.info/ViewCover.aspx?id=267